![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCDC71 |
Gene summary for CCDC71 |
![]() |
Gene information | Species | Human | Gene symbol | CCDC71 | Gene ID | 64925 |
Gene name | coiled-coil domain containing 71 | |
Gene Alias | CCDC71 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8IV32 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64925 | CCDC71 | LZE4T | Human | Esophagus | ESCC | 5.01e-04 | 1.23e-01 | 0.0811 |
64925 | CCDC71 | LZE24T | Human | Esophagus | ESCC | 3.11e-08 | 2.13e-01 | 0.0596 |
64925 | CCDC71 | P2T-E | Human | Esophagus | ESCC | 4.44e-08 | 1.79e-01 | 0.1177 |
64925 | CCDC71 | P4T-E | Human | Esophagus | ESCC | 5.47e-11 | 2.97e-01 | 0.1323 |
64925 | CCDC71 | P5T-E | Human | Esophagus | ESCC | 4.92e-07 | 1.18e-01 | 0.1327 |
64925 | CCDC71 | P8T-E | Human | Esophagus | ESCC | 1.84e-10 | 8.02e-02 | 0.0889 |
64925 | CCDC71 | P9T-E | Human | Esophagus | ESCC | 1.60e-10 | 2.21e-01 | 0.1131 |
64925 | CCDC71 | P10T-E | Human | Esophagus | ESCC | 1.34e-17 | 1.91e-01 | 0.116 |
64925 | CCDC71 | P12T-E | Human | Esophagus | ESCC | 1.63e-18 | 1.65e-01 | 0.1122 |
64925 | CCDC71 | P15T-E | Human | Esophagus | ESCC | 8.56e-08 | 2.12e-01 | 0.1149 |
64925 | CCDC71 | P16T-E | Human | Esophagus | ESCC | 3.77e-19 | 3.03e-01 | 0.1153 |
64925 | CCDC71 | P20T-E | Human | Esophagus | ESCC | 4.04e-08 | 2.07e-01 | 0.1124 |
64925 | CCDC71 | P21T-E | Human | Esophagus | ESCC | 7.93e-23 | 3.46e-01 | 0.1617 |
64925 | CCDC71 | P22T-E | Human | Esophagus | ESCC | 1.42e-07 | 1.34e-01 | 0.1236 |
64925 | CCDC71 | P23T-E | Human | Esophagus | ESCC | 6.94e-12 | 3.11e-01 | 0.108 |
64925 | CCDC71 | P24T-E | Human | Esophagus | ESCC | 3.01e-16 | 2.63e-01 | 0.1287 |
64925 | CCDC71 | P26T-E | Human | Esophagus | ESCC | 1.98e-20 | 1.91e-01 | 0.1276 |
64925 | CCDC71 | P27T-E | Human | Esophagus | ESCC | 3.58e-15 | 1.53e-01 | 0.1055 |
64925 | CCDC71 | P28T-E | Human | Esophagus | ESCC | 5.09e-07 | 6.08e-02 | 0.1149 |
64925 | CCDC71 | P30T-E | Human | Esophagus | ESCC | 4.62e-04 | 2.36e-01 | 0.137 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
GO:00456006 | Oral cavity | OSCC | positive regulation of fat cell differentiation | 41/7305 | 66/18723 | 1.20e-04 | 8.60e-04 | 41 |
GO:004560013 | Oral cavity | EOLP | positive regulation of fat cell differentiation | 17/2218 | 66/18723 | 1.41e-03 | 9.58e-03 | 17 |
GO:004544415 | Oral cavity | EOLP | fat cell differentiation | 42/2218 | 229/18723 | 2.58e-03 | 1.56e-02 | 42 |
GO:004559812 | Oral cavity | EOLP | regulation of fat cell differentiation | 28/2218 | 139/18723 | 3.29e-03 | 1.90e-02 | 28 |
GO:004560022 | Oral cavity | NEOLP | positive regulation of fat cell differentiation | 24/2005 | 66/18723 | 3.20e-08 | 1.35e-06 | 24 |
GO:004559821 | Oral cavity | NEOLP | regulation of fat cell differentiation | 37/2005 | 139/18723 | 1.12e-07 | 4.05e-06 | 37 |
GO:004544422 | Oral cavity | NEOLP | fat cell differentiation | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
GO:00454447 | Prostate | BPH | fat cell differentiation | 59/3107 | 229/18723 | 2.60e-04 | 2.04e-03 | 59 |
GO:00455982 | Prostate | BPH | regulation of fat cell differentiation | 36/3107 | 139/18723 | 3.43e-03 | 1.76e-02 | 36 |
GO:00456005 | Prostate | BPH | positive regulation of fat cell differentiation | 20/3107 | 66/18723 | 4.09e-03 | 2.03e-02 | 20 |
GO:004544414 | Prostate | Tumor | fat cell differentiation | 69/3246 | 229/18723 | 1.22e-06 | 2.28e-05 | 69 |
GO:004559811 | Prostate | Tumor | regulation of fat cell differentiation | 39/3246 | 139/18723 | 1.11e-03 | 7.12e-03 | 39 |
GO:004560012 | Prostate | Tumor | positive regulation of fat cell differentiation | 22/3246 | 66/18723 | 1.21e-03 | 7.66e-03 | 22 |
GO:004544418 | Thyroid | PTC | fat cell differentiation | 102/5968 | 229/18723 | 3.66e-05 | 3.40e-04 | 102 |
GO:004560015 | Thyroid | PTC | positive regulation of fat cell differentiation | 33/5968 | 66/18723 | 1.63e-03 | 9.01e-03 | 33 |
GO:004559814 | Thyroid | PTC | regulation of fat cell differentiation | 59/5968 | 139/18723 | 5.50e-03 | 2.50e-02 | 59 |
GO:004544423 | Thyroid | ATC | fat cell differentiation | 105/6293 | 229/18723 | 7.42e-05 | 5.62e-04 | 105 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC71 | SNV | Missense_Mutation | novel | c.826C>G | p.Leu276Val | p.L276V | Q8IV32 | protein_coding | tolerated(0.14) | benign(0.282) | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCDC71 | SNV | Missense_Mutation | novel | c.1245N>T | p.Trp415Cys | p.W415C | Q8IV32 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCDC71 | SNV | Missense_Mutation | novel | c.521N>T | p.Arg174Leu | p.R174L | Q8IV32 | protein_coding | deleterious(0) | possibly_damaging(0.846) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCDC71 | SNV | Missense_Mutation | novel | c.1192N>T | p.Asp398Tyr | p.D398Y | Q8IV32 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCDC71 | SNV | Missense_Mutation | c.196N>T | p.Arg66Cys | p.R66C | Q8IV32 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC71 | SNV | Missense_Mutation | c.859C>G | p.Arg287Gly | p.R287G | Q8IV32 | protein_coding | deleterious(0) | benign(0.001) | TCGA-BC-A5W4-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
CCDC71 | SNV | Missense_Mutation | c.218N>G | p.Tyr73Cys | p.Y73C | Q8IV32 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CC-A7II-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
CCDC71 | SNV | Missense_Mutation | novel | c.785N>G | p.Thr262Ser | p.T262S | Q8IV32 | protein_coding | tolerated(0.89) | benign(0.005) | TCGA-DD-AAE7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCDC71 | SNV | Missense_Mutation | novel | c.472G>T | p.Ala158Ser | p.A158S | Q8IV32 | protein_coding | tolerated(0.1) | benign(0.014) | TCGA-ZS-A9CF-02 | Liver | NA | NA | NA | NA | NA | NA | NA |
CCDC71 | SNV | Missense_Mutation | c.311N>T | p.Arg104Leu | p.R104L | Q8IV32 | protein_coding | deleterious(0.02) | benign(0.098) | TCGA-86-7701-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |